UNITED THERAPEUTICS CORP.

Products

Category

Product

Brand

Description

Cardiovascular Drugs: Global Markets to 2030 (PHM191B)

Remodulin		Remodulin is used to treat pulmonary arterial hypertension (PAH). It works by dilating pulmonary blood vessels, reducing vascular resistance, and improving blood flow from the heart to the lungs, helping improve exercise capacity.
Tyvaso / Tyvaso DPI		Tyvaso and Tyvaso DPI are inhaled therapies for pulmonary hypertension associated with PAH or interstitial lung disease. These help relax pulmonary arteries, lowering pressure and supporting proper heart function.
Orenitram		Orenitram is an oral treatment for pulmonary arterial hypertension. It improves circulation in the pulmonary vasculature, reducing strain on the heart and supporting long-term disease management.

This information is available for BCC Research members only.

Already a Member? Sign In Become a Member

Stay Informed

Join our mailing list for the latest report releases and upcoming event notifications.

Headquartered in Boston, Mass., for over 50 years, BCC Research takes pride in being your trusted custom research and data analysts. Our mission is to provide businesses with reputable data and market research reports, so that they gain new perspectives into their field and better understand their target audience. We enable companies to access reliable information, accurate forecasts, and actionable insights, so that they may become leaders in their industry.

AI Sentiment